NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Arbutus Biopharma Corp. ABUS
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$14.1M
▲ 128.2% vs FY2024
EPS · FY25
$-0.17
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-38.5%
Net margin · FY25
-237.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 14.1M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 238 cents on every revenue dollar this year.
Per share
USD -0.17
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-38.5%
Return on equity, FY2025
ROE
Operating margin-271.0%
Net margin-237.9%
Return on assets-29.6%
Each USD of equity lost 39 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+15.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−28.8%
+15.3%
−4.9%
−2.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.19B
Shares outstanding, FY2025
Change, 5 years+64.3%
Change, 10 years—
The share count grew 64% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 94.6M
total assets, end of FY2025
Total assetsUSD 94.6M
EquityUSD 76.6M
CashUSD 18.0M
Gross debtUSD 0.00
Net debtUSD -18.0M
Current ratio15.73×
The company holds more cash than debt.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.5
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.5
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.1
−0.0
0.0
0.0
·
·
·
·
Net income $B
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
−0.1
−0.1
−0.4
−0.1
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.17
−0.38
−0.44
−0.46
−0.83
−1.00
−2.89
−1.21
−1.56
−7.24
−1.38
−1.80
−0.92
2.07
−0.89
−1.20
−0.85
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−38.5
−68.8
−60.0
−45.4
−56.2
−73.0
−112.6
−29.8
−43.8
−102.4
−19.7
−52.8
−28.1
128.3
−125.9
−74.7
−39.0
Shares out B
0.19
0.19
0.17
0.16
0.14
0.09
0.06
0.06
0.06
0.05
0.05
0.02
0.02
0.01
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed